Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma

PURPOSE: To investigate quality-adjusted progression-free survival (QA-PFS) and quality-adjusted time without symptoms or toxicity (Q-TWiST) in a post hoc exploratory analysis of the phase III ARIEL3 study of rucaparib maintenance treatment versus placebo. PATIENTS AND METHODS: Patients with platinu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Oza, Amit M., Lorusso, Domenica, Aghajanian, Carol, Oaknin, Ana, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I., Clamp, Andrew R., Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W., Gancedo, Margarita Amenedo, Fong, Peter C., Goh, Jeffrey C., O’Malley, David M., Armstrong, Deborah K., Banerjee, Susana, García-Donas, Jesus, Swisher, Elizabeth M., Cella, David, Meunier, Juliette, Goble, Sandra, Cameron, Terri, Maloney, Lara, Mörk, Ann-Christin, Bedel, Josh, Ledermann, Jonathan A., Coleman, Robert L.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2020
Assuntos:
RAPID COMMUNICATIONS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7571791/
https://ncbi.nlm.nih.gov/pubmed/32840418
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.03107
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados